SBIR/STTR Research Award

Rapid Non-Viral Platform for Generation of Genetically Modified T Cells for Therapy

Award identifier b77b3e391df40f913abaff0919d965f66ee3a527a898ef1b8e522ae6ee3fa47eAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$218,588

Program and phase

SBIR · Phase I

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
B-MoGen Biotechnologies Inc
Proposal award date
2018-08-06
Contract end date
2019-05-05
UEI
Not reported
Solicitation number
PA17-302
Topic code
100

Research abstract

Abstract Cancer immunotherapyparticularly genetically engineered adoptive T cell transferhas shown great potential for the treatment of cancer patientsThe use of T cells engineered to express a specific T cell receptorTCRsor chimeric antigen receptorCARsto treat cancer has generated durable cures for many cancer patients and has resulted in the first FDA approved CAR T therapy to treat childhood acute lymphoblastic leukemia inMost gene therapies rely on viral methods to genetically modify human primary cellsHoweverviral delivery method is expensivepoorly reproducible and associated with several safety concerns including insertion in or near genes that may cause malignancy and generation of replication competent virusThusnon viral DNA delivery methodssuch as Sleeping Beauty and piggyBachave been employed to generate CAR T cellsAlthough these non viral delivery methods have the advantage of lower costimmunogenicityand regulatory considerationsthey have been limited by their low transposition efficiency in primary human hematopoietic cellsIn this applicationwe propose to rationally optimize a recently discovered transposonTcBuster to deliver CARs to T cellsTo this endwe further enhance our already very active hyperactive mutants of the TcBuster transposase and optimize the delivery of the transposon into cellsFollowing optimization of the TcBuster transposon systemwe will combine these improvements with our proprietary methods to transfect T cells efficiently and safelyand test the immunotherapeutic effectiveness of TcBuster delivered CAR into T cellsThe successful completion of this project will result in the comprehensive methods to produce CAR T cells delivered by TcBuster which we will license to pharmaceutical companies to produce highly efficient CAR T immunotherapyMore broadlythese methods could be expanded beyond immunotherapeutic cancer applications to various infectious diseases in which gene delivery by TcBuster in T cells could be advantageous

Technology keywords

Not reported

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.